Functional assessments in repeat-dose toxicity studies: the art of the possible
Abstract
Clinical and nonclinical safety liabilities remain a major cause of adverse
Maintenance work is planned from 09:00 BST to 12:00 BST on Saturday 28th September 2024.
During this time the performance of our website may be affected - searches may run slowly, some pages may be temporarily unavailable, and you may be unable to access content. If this happens, please try refreshing your web browser or try waiting two to three minutes before trying again.
We apologise for any inconvenience this might cause and thank you for your patience.
* Corresponding authors
a
Global Safety Assessment, AstraZeneca R&D, Alderley Park, Cheshire SK10 4TG, United Kingdom
E-mail:
will.redfern@astrazeneca.com
Clinical and nonclinical safety liabilities remain a major cause of adverse
Fetching data from CrossRef.
This may take some time to load.
Loading related content